MASP-2 Inhibition for Selective Lectin Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors, such as Eculizumab, target downstream molecules like C5, which do not effectively inhibit the initiation steps of complement activation, leading to potential host tissue damage in various disease states, and there is a need for inhibitors that can specifically target the initiation steps of the complement system.
Innovation Solution
Development of MASP-2 inhibitory agents, including anti-MASP-2 antibodies and peptides, to inhibit MASP-2-dependent complement activation without affecting the classical or C1q-dependent system, thereby reducing adverse effects on host tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If downstream complement inhibitors like Eculizumab (anti-C5) are used, then complement-mediated tissue injury is reduced, but the initiation steps of complement activation are not inhibited, allowing continued pathological activation
Solution Approach 1:
The patent extracts and targets the specific initiation step of the lectin pathway by developing MASP-2 inhibitors. Instead of blocking downstream effects with anti-C5 antibodies, the invention isolates and inhibits MASP-2, the serine protease responsible for C4 and C2 cleavage in the lectin pathway, thereby preventing complement activation at its source while leaving the classical pathway intact
Solution Approach 2:
The patent segments the complement inhibition approach by creating pathway-specific inhibitors. MASP-2 inhibitors selectively block the lectin pathway initiation step while preserving the classical pathway (C1q-dependent system). This segmentation allows targeted inhibition of pathological lectin pathway activation without compromising overall complement function or immune defense
2Object-affected harmful factors
If MASP-2 inhibitory agents are used to specifically block lectin pathway initiation, then tissue damage is minimized, but there is a risk of affecting other complement pathways
Solution Approach 1:
The patent uses MASP-2 as a specific intermediary target in the lectin pathway. MASP-2 serves as the unique serine protease mediator that cleaves C4 and C2 to form the C3 convertase (C4b2a) in the lectin pathway. By targeting this specific intermediary enzyme, the invention achieves selective lectin pathway inhibition without affecting the classical pathway, which uses a different protease system (C1r/C1s)
Solution Approach 2:
The patent applies local quality by creating an inhibitor with specific action at the MASP-2 site in the lectin pathway. The MASP-2 inhibitory agent is designed to bind specifically to MASP-2 and block its proteolytic activity on C4 and C2, while having no effect on other complement components or pathways. This localized inhibition at the specific MASP-2 target site provides high selectivity and pathway-specific action
Data Source
AI summary
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.